Long term outcomes of a randomized controlled clinical trial comparing the efficacy of Cabazitaxel versus docetaxel as second-line or above therapy in recurrent head and neck cancer

Vijay Patil; Sravan Kumar; Vanita Noronha; Nandini Menon; Kavita Prakash Nawale; Mitali Alone; Gopichand Waratkar; Sachin Dhumal; Atanu Bhattacharjee; Kumar Prabhash

doi:10.1016/j.oraloncology.2022.106085

Long term outcomes of a randomized controlled clinical trial comparing the efficacy of Cabazitaxel versus docetaxel as second-line or above therapy in recurrent head and neck cancer

Vijay Patil
, Sravan Kumar
, Vanita Noronha
, Nandini Menon
, Kavita Prakash Nawale
, Mitali Alone
, Gopichand Waratkar
, Sachin Dhumal
, Atanu Bhattacharjee
, Kumar Prabhash (Lead / Corresponding author)

Population Health and Genomics

Research output: Contribution to journal › Letter › peer-review

1 Citation (Scopus)

Original language	English
Article number	106085
Number of pages	4
Journal	Oral Oncology
Volume	134
Early online date	18 Sept 2022
DOIs	https://doi.org/10.1016/j.oraloncology.2022.106085
Publication status	Published - Nov 2022

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Keywords

Antineoplastic Combined Chemotherapy Protocols/therapeutic use
Docetaxel/therapeutic use
Head and Neck Neoplasms/drug therapy
Humans
Neoplasm Recurrence, Local/drug therapy
Taxoids/therapeutic use
Treatment Outcome

Access to Document

10.1016/j.oraloncology.2022.106085

Cite this

Patil, V., Kumar, S., Noronha, V., Menon, N., Nawale, K. P., Alone, M., Waratkar, G., Dhumal, S., Bhattacharjee, A., & Prabhash, K. (2022). Long term outcomes of a randomized controlled clinical trial comparing the efficacy of Cabazitaxel versus docetaxel as second-line or above therapy in recurrent head and neck cancer. Oral Oncology, 134, Article 106085. https://doi.org/10.1016/j.oraloncology.2022.106085

@article{d1e64eac8a6049fbaaa96052bdaea8da,

title = "Long term outcomes of a randomized controlled clinical trial comparing the efficacy of Cabazitaxel versus docetaxel as second-line or above therapy in recurrent head and neck cancer",

keywords = "Antineoplastic Combined Chemotherapy Protocols/therapeutic use, Docetaxel/therapeutic use, Head and Neck Neoplasms/drug therapy, Humans, Neoplasm Recurrence, Local/drug therapy, Taxoids/therapeutic use, Treatment Outcome",

author = "Vijay Patil and Sravan Kumar and Vanita Noronha and Nandini Menon and Nawale, \{Kavita Prakash\} and Mitali Alone and Gopichand Waratkar and Sachin Dhumal and Atanu Bhattacharjee and Kumar Prabhash",

year = "2022",

month = nov,

doi = "10.1016/j.oraloncology.2022.106085",

language = "English",

volume = "134",

journal = "Oral Oncology",

issn = "1368-8375",

publisher = "Elsevier",

}

Patil, V, Kumar, S, Noronha, V, Menon, N, Nawale, KP, Alone, M, Waratkar, G, Dhumal, S, Bhattacharjee, A & Prabhash, K 2022, 'Long term outcomes of a randomized controlled clinical trial comparing the efficacy of Cabazitaxel versus docetaxel as second-line or above therapy in recurrent head and neck cancer', Oral Oncology, vol. 134, 106085. https://doi.org/10.1016/j.oraloncology.2022.106085

TY - JOUR

T1 - Long term outcomes of a randomized controlled clinical trial comparing the efficacy of Cabazitaxel versus docetaxel as second-line or above therapy in recurrent head and neck cancer

AU - Patil, Vijay

AU - Kumar, Sravan

AU - Noronha, Vanita

AU - Menon, Nandini

AU - Nawale, Kavita Prakash

AU - Alone, Mitali

AU - Waratkar, Gopichand

AU - Dhumal, Sachin

AU - Bhattacharjee, Atanu

AU - Prabhash, Kumar

PY - 2022/11

Y1 - 2022/11

KW - Antineoplastic Combined Chemotherapy Protocols/therapeutic use

KW - Docetaxel/therapeutic use

KW - Head and Neck Neoplasms/drug therapy

KW - Humans

KW - Neoplasm Recurrence, Local/drug therapy

KW - Taxoids/therapeutic use

KW - Treatment Outcome

UR - https://www.scopus.com/pages/publications/85138109343

U2 - 10.1016/j.oraloncology.2022.106085

DO - 10.1016/j.oraloncology.2022.106085

M3 - Letter

C2 - 36126602

SN - 1368-8375

VL - 134

JO - Oral Oncology

JF - Oral Oncology

M1 - 106085

ER -

Long term outcomes of a randomized controlled clinical trial comparing the efficacy of Cabazitaxel versus docetaxel as second-line or above therapy in recurrent head and neck cancer

UN SDGs

Keywords

Access to Document

Other files and links

Cite this